Foundayo is a small molecule that works as a GLP-1 Receptor Agonist.[2] It is being used across 6 indications, with its most advanced program in Approved.[1]
Foundayo is one of 142 small molecule programs targeting Hyperglycemia. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Application
NDA/BLA/ANDA regulatory filings
Patents
Pipeline
Competition
177 competitors in Obesity
Foundayo
Vivia
Berobenatide
HRS9531
NNC0487-0111
Zenagamtide
PF-08653944
Efsubaglutide Alfa
Actemra
Avapro
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Apr 1, 2026
FOUNDAYO
NDA NDA220934
Sources